LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

Search

REVOLUTION Medicines Inc

Gesloten

SectorGezondheidszorg

44.02 -1.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.72

Max

45.15

Belangrijke statistieken

By Trading Economics

Inkomsten

-34M

-248M

EPS

-1.13

Winstmarge

-74.379

Werknemers

700

EBITDA

-24M

-261M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+54.2% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

750M

7.7B

Vorige openingsprijs

45.54

Vorige sluitingsprijs

44.02

Nieuwssentiment

By Acuity

33%

67%

113 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 sep 2025, 17:03 UTC

Belangrijke Marktbewegers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sep 2025, 16:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

GD Culture Shares Drop After Deal for Pallas Capital

16 sep 2025, 16:11 UTC

Belangrijke Marktbewegers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sep 2025, 23:40 UTC

Marktinformatie

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sep 2025, 23:34 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sep 2025, 23:20 UTC

Marktinformatie

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sep 2025, 21:10 UTC

Acquisities, Fusies, Overnames

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sep 2025, 20:51 UTC

Marktinformatie

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 20:25 UTC

Winsten

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sep 2025, 20:24 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sep 2025, 19:19 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sep 2025, 18:52 UTC

Marktinformatie

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sep 2025, 18:40 UTC

Acquisities, Fusies, Overnames

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sep 2025, 18:38 UTC

Marktinformatie

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sep 2025, 18:19 UTC

Marktinformatie

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sep 2025, 18:01 UTC

Marktinformatie

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sep 2025, 17:34 UTC

Marktinformatie

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sep 2025, 16:53 UTC

Winsten

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sep 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 16:15 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Commodities Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Energy Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sep 2025, 15:22 UTC

Marktinformatie

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sep 2025, 15:21 UTC

Marktinformatie

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

54.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.24 USD  54.2%

Hoogste 80 USD

Laagste 37.91 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

113 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat